Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index.

ABSTRACT:

Background and aim

Non-alcoholic fatty liver disease (NAFLD) initially presents as steatosis, which can progress to non-alcoholic steatohepatitis (NASH), and often presents clinically alongside metabolic syndromes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are regularly utilized to treat type 2 diabetes mellitus. The GLP-1 RA-liraglutide-ameliorates liver enzymes, histological features, and liver fat content of patients with NASH. However, few studies have examined whether the effect of GLP-1 RAs depends on changes in the patient's body mass index (BMI). Therefore, this retrospective study aimed to investigate whether the efficacy of liraglutide depended on the baseline BMI or a reduction in BMI.

Methods

Fifty-five Japanese patients with type 2 diabetes mellitus

SUBMITTER: Shiomi M 

PROVIDER: S-EPMC7578289 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature